Y Intercept Hong Kong Ltd Lowers Stock Holdings in uniQure N.V. $QURE

by · The Cerbat Gem

Y Intercept Hong Kong Ltd lessened its holdings in shares of uniQure N.V. (NASDAQ:QURE – Free Report) by 63.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,704 shares of the biotechnology company’s stock after selling 39,834 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in uniQure were worth $1,325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in QURE. Private Trust Co. NA purchased a new position in uniQure during the third quarter worth about $28,000. Main Management ETF Advisors LLC lifted its holdings in shares of uniQure by 1.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 912 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of uniQure by 358.0% in the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,538 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in uniQure in the third quarter valued at approximately $454,000. Finally, KLP Kapitalforvaltning AS acquired a new position in uniQure during the second quarter worth approximately $117,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on QURE shares. HC Wainwright lowered their price objective on shares of uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Stifel Nicolaus lowered their price target on uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Wells Fargo & Company cut their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, November 12th. Mizuho decreased their target price on uniQure from $60.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, December 8th. Finally, Chardan Capital reissued a “buy” rating and set a $53.00 target price on shares of uniQure in a research report on Thursday, December 4th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $58.33.

Read Our Latest Research Report on QURE

uniQure Stock Down 4.0%

Shares of NASDAQ QURE opened at $22.72 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. uniQure N.V. has a 1 year low of $7.76 and a 1 year high of $71.50. The stock’s 50-day simple moving average is $23.63 and its 200-day simple moving average is $28.33. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -5.18 and a beta of 0.68.

uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, equities analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Robert Gut sold 31,434 shares of uniQure stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the transaction, the director directly owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at approximately $620,119.26. This trade represents a 65.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 102,247 shares of company stock worth $2,839,298. Insiders own 4.79% of the company’s stock.

uniQure Company Profile

(Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.

Featured Articles

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE – Free Report).